Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma.
Liu
Howard L
HL
Kim
Youn H
YH
D016588:Anticarcinogenic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000077610:Bexarotene; D017277:Drug Approval; D005782:Gels; D006801:Humans; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage* / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D005782:Gels; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene